Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 10 2019
Historique:
received: 07 08 2019
accepted: 09 10 2019
entrez: 31 10 2019
pubmed: 31 10 2019
medline: 20 11 2020
Statut: epublish

Résumé

Synonymous codons occur with different frequencies in different organisms, a phenomenon termed codon usage bias. Codon optimization, a common term for a variety of approaches used widely by the biopharmaceutical industry, involves synonymous substitutions to increase protein expression. It had long been presumed that synonymous variants, which, by definition, do not alter the primary amino acid sequence, have no effect on protein structure and function. However, a critical mass of reports suggests that synonymous codon variations may impact protein conformation. To investigate the impact of synonymous codons usage on protein expression and function, we designed an optimized coagulation factor IX (FIX) variant and used multiple methods to compare its properties to the wild-type FIX upon expression in HEK293T cells. We found that the two variants differ in their conformation, even when controlling for the difference in expression levels. Using ribosome profiling, we identified robust changes in the translational kinetics of the two variants and were able to identify a region in the gene that may have a role in altering the conformation of the protein. Our data have direct implications for codon optimization strategies, for production of recombinant proteins and gene therapies.

Identifiants

pubmed: 31664102
doi: 10.1038/s41598-019-51984-2
pii: 10.1038/s41598-019-51984-2
pmc: PMC6820528
doi:

Substances chimiques

Codon 0
Factor IX 9001-28-9

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

15449

Subventions

Organisme : NHLBI NIH HHS
ID : R15 HL121779
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER)
ID : HL121779
Pays : International

Références

BMC Bioinformatics. 2017 Sep 2;18(1):391
pubmed: 28865429
Nucleic Acid Ther. 2013 Dec;23(6):435-42
pubmed: 24152208
PLoS One. 2011 Mar 03;6(3):e17596
pubmed: 21408612
Neurobiol Dis. 2006 Aug;23(2):342-50
pubmed: 16730180
PLoS One. 2010 Dec 07;5(12):e15004
pubmed: 21165148
J Biol Chem. 1995 Sep 29;270(39):22801-6
pubmed: 7559409
PeerJ. 2017 Mar 9;5:e3081
pubmed: 28289571
Anal Bioanal Chem. 2018 Jan;410(2):297-306
pubmed: 28884330
Mol Ther. 2014 Mar;22(3):567-574
pubmed: 23941813
J Biol Chem. 2010 Sep 10;285(37):28741-8
pubmed: 20628052
PLoS One. 2012;7(2):e31948
pubmed: 22384109
Philos Trans R Soc Lond B Biol Sci. 2017 Mar 19;372(1716):
pubmed: 28138068
FEBS Lett. 1999 Dec 3;462(3):387-91
pubmed: 10622731
Sci Rep. 2019 Feb 1;9(1):1111
pubmed: 30710098
Nat Methods. 2015 Sep;12(9):835-837
pubmed: 26214130
Annu Rev Biophys. 2015;44:143-66
pubmed: 25747594
Trends Mol Med. 2014 Nov;20(11):604-13
pubmed: 25263172
Am J Physiol Gastrointest Liver Physiol. 2019 Jun 1;316(6):G720-G734
pubmed: 30920299
Science. 2007 Jan 26;315(5811):525-8
pubmed: 17185560
Nucleic Acids Res. 2017 May 19;45(9):5437-5448
pubmed: 28158713
Int J Biochem Cell Biol. 2015 Jul;64:58-74
pubmed: 25817479
J Comput Chem. 2011 Jan 15;32(1):170-3
pubmed: 20645303
Mol Cell. 2016 Feb 4;61(3):341-351
pubmed: 26849192
Trends Genet. 2014 Jul;30(7):308-21
pubmed: 24954581
J Mol Biol. 2019 Jun 14;431(13):2434-2441
pubmed: 31029701
J Med Genet. 2017 May;54(5):338-345
pubmed: 28007939
Nat Genet. 2002 Apr;30(4):377-84
pubmed: 11925564
Protein Sci. 1996 Aug;5(8):1594-612
pubmed: 8844849
Science. 2015 Apr 24;348(6233):444-8
pubmed: 25908822
Nucleic Acids Res. 1987 Feb 11;15(3):1281-95
pubmed: 3547335
J Mol Biol. 1981 Feb 15;146(1):1-21
pubmed: 6167728
Methods Mol Med. 2004;94:197-210
pubmed: 14959831
Mol Genet Genomic Med. 2019 Aug;7(8):e840
pubmed: 31257730
Nat Genet. 2011 Mar;43(3):242-5
pubmed: 21278745
Cell. 2011 Nov 11;147(4):789-802
pubmed: 22056041
Methods. 2017 Aug 15;126:112-129
pubmed: 28579404
Biochem Soc Trans. 1993 Nov;21(4):835-41
pubmed: 8132077
Syst Synth Biol. 2010 Sep;4(3):215-25
pubmed: 21189842
BioDrugs. 2018 Feb;32(1):69-81
pubmed: 29392566
Protein Sci. 2017 Jul;26(7):1352-1362
pubmed: 28480640
Science. 2009 Apr 10;324(5924):218-23
pubmed: 19213877
Cell. 2015 Mar 12;160(6):1111-24
pubmed: 25768907
Science. 1973 Jul 20;181(4096):223-30
pubmed: 4124164
Elife. 2014 May 09;3:e01257
pubmed: 24842990
Blood. 2019 Jan 31;133(5):389-398
pubmed: 30559264
Nucleic Acids Symp Ser. 1995;(34):97-8
pubmed: 8841570
J Mol Evol. 1997 Nov;45(5):514-23
pubmed: 9342399
Nucleic Acids Res. 2019 Jun 4;47(10):4974-4985
pubmed: 30916348
Haemophilia. 2017 Jan;23(1):e8-e17
pubmed: 27933712
Haemophilia. 2019 Jul;25(4):e240-e246
pubmed: 31131515
PLoS Biol. 2017 May 16;15(5):e2000779
pubmed: 28510592
BMC Genomics. 2017 Mar 13;18(1):227
pubmed: 28288557
Protein J. 2019 Jun;38(3):317-329
pubmed: 31004255
Cell Syst. 2017 Sep 27;5(3):212-220.e6
pubmed: 28957655
Nucleic Acids Res. 2004 Sep 24;32(17):5036-44
pubmed: 15448185
Trends Genet. 2000 Jul;16(7):287-9
pubmed: 10858656
PLoS Comput Biol. 2019 May 23;15(5):e1007070
pubmed: 31120880
Mol Cell. 2015 Sep 3;59(5):744-54
pubmed: 26321254
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13481-6
pubmed: 23901115
J Gen Virol. 1991 Jul;72 ( Pt 7):1551-7
pubmed: 1713260
Elife. 2014 Oct 27;3:
pubmed: 25347064
PLoS One. 2013;8(2):e53935
pubmed: 23393552
Translation (Austin). 2016 Sep 9;4(2):e1234431
pubmed: 28090420
Nucleic Acids Res. 2010 Jul;38(12):3891-908
pubmed: 20203083
Mol Immunol. 2004 Jan;40(10):717-22
pubmed: 14644097
Mol Biol Evol. 2017 Nov 1;34(11):2944-2958
pubmed: 28961875
Cell. 2015 Jun 18;161(7):1606-18
pubmed: 26052047
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):E1362-71
pubmed: 26903634
PLoS Biol. 2006 Jun;4(6):e180
pubmed: 16700628
Mol Ther Methods Clin Dev. 2018 Dec 31;12:184-201
pubmed: 30705923

Auteurs

Aikaterini Alexaki (A)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Gaya K Hettiarachchi (GK)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

John C Athey (JC)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Upendra K Katneni (UK)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Vijaya Simhadri (V)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Nobuko Hamasaki-Katagiri (N)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Puja Nanavaty (P)

Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH, USA.

Brian Lin (B)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Kazuyo Takeda (K)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Darón Freedberg (D)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Dougald Monroe (D)

University of North Carolina at Chapel hill, Chapel hill, NC, USA.

Joseph R McGill (JR)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Robert Peters (R)

Bioverativ, Cambridge, MA, USA.

Jacob M Kames (JM)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

David D Holcomb (DD)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Ryan C Hunt (RC)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Zuben E Sauna (ZE)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Amy Gelinas (A)

SomaLogic, Inc, Boulder, CO, USA.

Nebojsa Janjic (N)

SomaLogic, Inc, Boulder, CO, USA.

Michael DiCuccio (M)

National Center of Biotechnology Information, National Institutes of Health, Bethesda, MD, USA.

Haim Bar (H)

Department of Statistics, University of Connecticut, Storrs, CT, USA.

Anton A Komar (AA)

Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH, USA.

Chava Kimchi-Sarfaty (C)

Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Chava.kimchi-sarfaty@fda.hhs.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH